Yipinhong Pharmaceutical updates governance, approves stock plan, R&D boost

Yipinhong Pharmaceutical's third extraordinary general meeting of shareholders on November 18, 2025, approved adjustments to its corporate governance structure and revisions to company articles and management policies. Key resolutions included amendments to the "Shareholder Meeting Rules," "Board of Directors Meeting Rules," and "Independent Director Work System." Concurrently, the company's fourth board of directors' thirteenth meeting approved the unlocking conditions for the first phase of its 2024 employee stock ownership plan, releasing 1,534,831 shares, or 0.34% of the total share capital.

The company also announced the resignation of non-independent director Ms. Yang Dongling due to governance adjustments and the election of Ms. Huang Liangwen as a worker director, effective November 18, 2025. Additionally, the board approved a change in the technical service contract with Guangzhou Boji Medical Technology Co., Ltd., increasing clinical research expenses by 2.245 billion yuan, bringing the total contract value to 9.208 billion yuan. These changes reflect the company's strategic adjustments and ongoing commitment to R&D and employee incentives.